JP2014526559A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526559A5
JP2014526559A5 JP2014531996A JP2014531996A JP2014526559A5 JP 2014526559 A5 JP2014526559 A5 JP 2014526559A5 JP 2014531996 A JP2014531996 A JP 2014531996A JP 2014531996 A JP2014531996 A JP 2014531996A JP 2014526559 A5 JP2014526559 A5 JP 2014526559A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
mab
efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014531996A
Other languages
English (en)
Japanese (ja)
Other versions
JP6204915B2 (ja
JP2014526559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056492 external-priority patent/WO2013043973A2/en
Publication of JP2014526559A publication Critical patent/JP2014526559A/ja
Publication of JP2014526559A5 publication Critical patent/JP2014526559A5/ja
Application granted granted Critical
Publication of JP6204915B2 publication Critical patent/JP6204915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014531996A 2011-09-23 2012-09-21 悪液質治療 Active JP6204915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538309P 2011-09-23 2011-09-23
US61/538,309 2011-09-23
PCT/US2012/056492 WO2013043973A2 (en) 2011-09-23 2012-09-21 Cachexia treatment

Publications (3)

Publication Number Publication Date
JP2014526559A JP2014526559A (ja) 2014-10-06
JP2014526559A5 true JP2014526559A5 (enExample) 2015-10-29
JP6204915B2 JP6204915B2 (ja) 2017-09-27

Family

ID=47911521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531996A Active JP6204915B2 (ja) 2011-09-23 2012-09-21 悪液質治療

Country Status (16)

Country Link
US (2) US9809649B2 (enExample)
EP (1) EP2750709B1 (enExample)
JP (1) JP6204915B2 (enExample)
KR (1) KR102039198B1 (enExample)
CN (2) CN108404127B (enExample)
AU (1) AU2012312225B2 (enExample)
CA (1) CA2849710C (enExample)
DK (1) DK2750709T3 (enExample)
ES (1) ES2695102T3 (enExample)
IL (1) IL231622B (enExample)
MX (1) MX356808B (enExample)
PH (1) PH12014500645A1 (enExample)
PT (1) PT2750709T (enExample)
RU (1) RU2622021C2 (enExample)
WO (1) WO2013043973A2 (enExample)
ZA (1) ZA201402057B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
RU2013110030A (ru) 2010-08-23 2014-09-27 ИксБиотеч, Инк. Лечение неопластических заболеваний
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JPH08502300A (ja) 1992-10-14 1996-03-12 スターリング ウィンスロップ アイエヌシー． 治療および診断像形成組成物および方法
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
US20040086507A1 (en) 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
ME00204B (me) 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006001967A2 (en) 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
CA2591148A1 (en) 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
CN101253409A (zh) 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
AU2006298767B2 (en) 2005-09-28 2013-01-10 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
BRPI0709977A2 (pt) 2006-04-14 2011-08-02 Novartis Ag uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
JP2009537507A (ja) 2006-05-15 2009-10-29 エクスバイオテク インコーポレーティッド アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ES2374845T3 (es) 2006-05-22 2012-02-22 Xbiotech, Inc Tratamiento de cáncer con anticuerpos anti-il-1.
CL2007001536A1 (es) 2006-05-30 2008-01-25 Genentech Inc Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
NZ590033A (en) * 2008-05-30 2011-08-26 Xbiotech Inc Interleukin-1alpha antibodies and methods of use
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
CN102655880A (zh) 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
RU2013110030A (ru) 2010-08-23 2014-09-27 ИксБиотеч, Инк. Лечение неопластических заболеваний
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN103442733A (zh) 2011-04-01 2013-12-11 埃克斯生物科技公司 皮肤病学病状的治疗
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP4628162A3 (en) 2012-10-04 2025-12-03 XBiotech Inc. Treating vascular disease and complications thereof
EP2903643A4 (en) 2012-10-04 2016-06-15 Xbiotech Inc TREATMENT OF PSYCHIATRIC DISEASES

Similar Documents

Publication Publication Date Title
JP2014526559A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
NZ707377A (en) Combination therapy methods for treating proliferative diseases
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2010222367A5 (enExample)
JP2010522242A5 (enExample)
RU2014111662A (ru) Лечение кахексии
JP2015515475A5 (enExample)
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
IN2014DN07149A (enExample)
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2015531396A5 (enExample)
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
EP3238726A3 (en) Composition comprising interferon gamma and an hdac inhibitor or gonadotropin receptor signalling hormone
BRPI1008103A2 (pt) " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "
EP2910634A4 (en) VACCINE FOR THE PREVENTION OF SWINE DISEASE
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease